Follow us :
日本デスク
Site en français
Conseils en Propriété Industrielle / European Patent and Trademark Attorneys
PARIS
LYON
RENNES
MONTPELLIER
GRENOBLE
TOULOUSE
MUNICH
Client Login
News
Events
In France and abroad
Legal News
Current IP News
Press Room
Press Releases
INFORMATION COVID-19
Expertise
Patents
Life Sciences and Chemistry
IT / Mechanics / Physics
Focus on our EP Practice
Unitary Patent
Trademarks & Designs
Our expertise
Contracts, IP valuation & Data
Drafting of your contracts
IP asset valuation
GDPR compliance
IP Intelligence
Patentability Study
Freedom to operate
Anticipating developments
For the last 80 years, we have been assisting our clients in protecting, developing and defending their innovations and creations.
Training
IP TRAINING
IP Academy
5-day seminar
Publications
Last Published
Current IP News
published by our IP Attorneys
Search for a publication
All our articles organised
by theme, author, IP rights
Focus on
Discover a selection of our publications arranged by topic.
IPON Newsletter
Read our latest newsletter
Team
Partners
Our team
Find your contact among our employees
REGIMBEAU's Network
Our network of International Associates and our involvement in Professional Organisations
日本デスク
Japan Desk
Careers
Join us
Discover our current employment offers and send your application
Contact us
Paris
Lyon
Rennes
Montpellier
Grenoble
Toulouse
Munich
Home
>
Publications
>
Search for a publication
>
Article
SPC : The End of Neurim ?
SPC : The End of Neurim ?
Nicolas BOUQUIN
, French & European Patent Attorney and
Anne BOUTARIC
, Partner and French & European Patent Attorney
The Court of Justice of the European Union issued this Thursday its judgement in Santen (C-673/18, Santen SAS / Directeur général de l'Institut national de la propriété industrielle), a decision with very important implications for all actors in the pharma sector.
Published on: 13th Jul 2020
SPC
Download the article
Click here